Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) has achieved CE-IVDR certification for its complete QIAstat-Dx syndromic testing portfolio, including an enhanced Meningitis/Encephalitis (ME) Panel featuring 16 clinically relevant targets. The expanded ME Panel, launching in September 2025, uniquely includes cytomegalovirus (CMV) and exclusive detection of Streptococcus pyogenes.

The QIAstat-Dx system, with over 4,600 installations globally, delivers comprehensive results in about an hour and is available in two formats: the standard Analyzer version and the higher-capacity Rise version capable of 160 tests per day. The platform offers CE-IVDR certified panels for respiratory, gastrointestinal, and CNS infections, featuring a simplified one-step workflow requiring minimal hands-on time.

QIAGEN (NYSE: QGEN) has received FDA clearance for its QIAstat-Dx Rise, an enhanced version of its automated syndromic testing system. The new system offers significantly higher throughput, capable of processing up to 160 samples per day across eight analytical modules, including 16 batch samples and two urgent slots per run.

The system features automated loading and unloading of cartridges, priority handling of urgent samples, and minimal hands-on time, delivering results in about one hour. Initially launching with Respiratory Panel Plus and Respiratory Panel Mini, QIAGEN plans to expand the test menu with gastrointestinal panels in the coming months. The QIAstat-Dx platform has already achieved significant market penetration with over 4,600 instruments placed globally through H1 2025 across more than 100 countries.

QIAGEN (NYSE: QGEN) has announced the final terms of its new senior, unsecured net share settled convertible bonds due 2032. The company is issuing $750 million in convertible bonds with an initial conversion price of $64.6338 per share, representing a 40% premium above the reference share price of $46.1670.

Upon conversion, bondholders will receive cash equal to the bonds' par value plus shares equivalent to the underlying value. The settlement date is set for September 4, 2025, with trading to commence on Frankfurt's Open Market. The proceeds will be used for general corporate purposes and debt refinancing. QIAGEN has agreed to a 90-day lock-up period for similar securities.

QIAGEN (NYSE: QGEN) has announced the successful placement of new senior, unsecured net share settled convertible bonds due 2032. The offering totals $750 million in aggregate principal amount with a 2.0% annual coupon payable semi-annually.

The convertible bonds will feature an initial conversion price set at a 40% premium over the reference share price, which will be determined based on the volume weighted average price of QIAGEN shares on the NYSE on August 28, 2025. The company has agreed to a 90-day lock-up period following the settlement date, during which it won't sell similar securities or shares, subject to certain exceptions.

QIAGEN (NYSE: QGEN) has announced plans to issue senior, unsecured net share settled convertible bonds due 2032. The offering, targeted at non-US institutional investors, will have an aggregate volume of USD 750 million with minimum denominations of USD 200,000 each.

The bonds will have a 7-year maturity and feature an interest rate of 1.75% to 2.25% per annum, payable semi-annually. The conversion will involve approximately 11.2 million shares, representing about 5.1% of QIAGEN's current outstanding share capital. The initial conversion price will be set at a 40% to 45% premium over the reference share price.

The settlement date is scheduled for September 4, 2025, and the bonds will be traded on the Open Market segment of the Frankfurt Stock Exchange. The proceeds will be used for general corporate purposes, including refinancing existing debt.

QIAGEN (NYSE: QGEN) reported strong Q2 2025 results, exceeding guidance with net sales of $534 million, representing a 7% increase at actual rates and 6% at constant exchange rates (CER). The company achieved an adjusted operating income margin of 29.9%, up 1.5 percentage points from Q2 2024, and delivered adjusted diluted EPS of $0.60.

Key growth drivers included QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER), contributing to an 11% CER growth in diagnostic solutions. Based on strong H1 2025 performance, QIAGEN increased its FY 2025 outlook to 4-5% CER net sales growth and reaffirmed its adjusted diluted EPS target of $2.35 CER. The company has returned over $350 million to shareholders in 2025 through a synthetic share repurchase and its first-ever cash dividend.

QIAGEN (NYSE: QGEN) has launched QIAseq xHYB Long Read Panels, a new suite of target enrichment solutions designed for long-read sequencing of complex genomic regions. The panels are optimized for native long-read platforms, including PacBio's technology, and aim to improve analysis of structural variants, HLA typing, and repeat expansions.

Built on QIAGEN's hybrid-capture chemistry, the panels offer high target completeness, flexible formats including fixed panels for hereditary cancers and HLA typing, compatibility with high-molecular-weight DNA extraction kits, and integration with QIAGEN Digital Insights bioinformatics. The launch strengthens QIAGEN's position in providing solutions for both short- and long-read NGS technologies.

QIAGEN (NYSE: QGEN) has scheduled its Q2 2025 earnings release and conference call. The company will release its second quarter results on Tuesday, August 5, 2025, after market close at 22:05 Frankfurt time (21:05 London/16:05 New York).

The earnings conference call will be held the following day, Wednesday, August 6, at 15:30 Frankfurt time (14:30 London/09:30 New York). Participants can join through multiple channels including call-back registration, direct dial-in, or audio webcast. A replay of the conference call will be made available afterward.

QIAGEN (NYSE: QGEN) announced significant leadership changes and shareholder-friendly initiatives. Stephen H. Rusckowski, former Chairman, President and CEO of Quest Diagnostics, has been elected as Chairman of the Supervisory Board, succeeding Lawrence A. Rosen who stepped down after 12 years of service.

At the Annual General Meeting (AGM), with 80.4% shareholder representation, all proposed resolutions were approved, including two major financial initiatives: the company's first-ever annual cash dividend of $0.25 per share (approximately $54 million total) and a new synthetic share repurchase authorization of up to $500 million.

Following the AGM, QIAGEN's Supervisory Board now consists of eight members, implementing a planned reduction to historical levels while maintaining necessary expertise for the company's future development.